Rapid Diagnostic Tests(RDT) for malaria reduces over prescription by over 70%

Rapid Diagnostic Tests(RDT) for malaria reduces over prescription by over 70%

Using malaria rapid diagnostic tests (RDT) in registered drug shops in a highly endemic region in Uganda substantially reduced over diagnosis of malaria, improving the use of valuable malaria drugs, according to a new study published in PLOS ONE.

Most of the 15,000 patients that visited drug shops with a fever chose to buy an RDT when offered one by the trained vendors taking part in the study. Once they performed the test, results showed that less than 60% of the patients had, in fact, malaria. The vendors usually complied with the test results, reducing over prescription of malaria drugs by 73%.

The researchers from the Artemisinin-based Combination Therapy (ACT) Consortium (http://www.actconsortium.org) at the Ministry of Health in Uganda and the London School of Hygiene & Tropical Medicine in the UK carried out the study because up to 80% of malaria cases in Uganda are treated in the private sector.

The private sector is a common source of treatment in many other malaria-endemic areas, especially where there is poor access to public health facilities. Patients buy antimalarial drugs in shops to medicate themselves, although malaria is not always the cause of their fever, and thus inappropriate treatment is very common.

Prof. Anthony Mbonye from the Ugandan Ministry of Health and lead author of the study, said: “Our findings show that it is feasible to collaborate with the private health sector and introduce malaria RDTs in drug shops. The next step is to refine the strategy and understand the cost implications of scaling it up in Uganda. Our long term aim is to provide evidence to help the World Health Organization develop guidance to improve malaria treatment in the private sector.”

We suggest you read  SAP to fund technology for disease prevention and treatment in Africa

 

Dr Sian Clarke from the London School of Hygiene & Tropical Medicine, also a principal investigator in the research, said: “This study shows that RDTs can improve the use of ACTs – the most effective treatment for malaria – in drug shops, but it’s not without its challenges. These tests alone will not improve the treatment of other diseases. We now need to continue working with the Ministry of Health to investigate how to improve our approach and expand it to other common illnesses.”

At present, drug shop vendors usually treat patients based on their signs and symptoms without testing their blood for the presence of malaria parasites, as recommended by the World Health Organization. This can result in patients with a fever being over diagnosed with malaria and purchasing an ACT which they don’t need.

 

Microscopy is a method that requires laboratory equipment and qualified staff, while RDTs are alternative, simple tools that require minimal training to diagnose malaria. These rapid tests can help health workers and vendors in remote locations to prescribe the correct treatment for malaria.

 

An investigation conducted alongside the trial, published in Critical Public Health, found that despite their popularity, malaria tests were not a simple fix in the private sector. Patients welcomed the RDTs as well as government involvement in improving drug shops, and vendors “felt big” and more akin to qualified health workers in the public sector for being allowed to test blood. But researchers warn that this could give a false impression of vendors’ other skills and services, and regulation by authorities is needed.

We suggest you read  SALT is using Telephone helpline to improve treatment of HIV/AIDS in Uganda Healthcare

The team have recently received a new grant to investigate the feasibility of training and equipping registered drug shops to manage three key childhood diseases: malaria, pneumonia and diarrhoea.

The ACT Consortium is funded by a grant from the Bill & Melinda Gates Foundation to London School of Hygiene & Tropical Medicine.

 

Distributed by APO (African Press Organization) on behalf of ACT Consortium.

About the ACT Consortium

The ACT Consortium (http://www.actconsortium.org) is an international research collaboration working on 25 projects in 10 countries to answer key questions on malaria drug delivery. Since initiating activities in 2008, the Consortium has been working to optimise the use of Artemisinin-based Combination Therapy (ACT), the first-line treatment for the most dangerous form of malaria recommended by the World Health Organization. The projects investigate ways to improve the access and targeting of ACTs, as well as assessing their safety and quality. The ACT Consortium is based at the London School of Hygiene & Tropical Medicine and a member of the School’s Malaria Centre.

About the London School of Hygiene & Tropical Medicine

The London School of Hygiene & Tropical Medicine is a world-leading centre for research and postgraduate education in public and global health, with 3,900 students and more than 1,000 staff working in over 100 countries. The School is one of the highest-rated research institutions in the UK, and was recently cited as the world’s leading research-focused graduate school. Our mission is to improve health and health equity in the UK and worldwide; working in partnership to achieve excellence in public and global health research, education and translation of knowledge into policy and practice. www.lshtm.ac.uk

SOURCE

ACT Consortium

Share